The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

Efficace, Fabio; Rosti, Gianantonio; Breccia, Massimo; Cottone, Francesco; Giesinger, Johannes M.; Stagno, Fabio; Iurlo, Alessandra; Rossi, Andrea; Luciano, Luigia; Martino, Bruno; Galimberti, Sara; Turri, Diamante; Bergamaschi, Micaela; Tiribelli, Mario; Fava, Carmen; Angelucci, Emanuele; Mandelli, Franco; Baccarani, Michele

doi:10.1007/s00277-015-2541-6

Cited by 19 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Response, including deep MR, to TKI treatment in patients with CP CML can be influenced by numerous factors, such as risk score, sex, adherence, and dose intensity [35]. Likewise, HRQoL can be affected by patient and treatment characteristics, including age, sex, comorbidities, and the side effects of the TKIs used to treat CML [29,[36][37][38][39][40]. It is also expected that these factors may influence the relationship between MR and FACT-Leu total score on an individual patient level.…”

Section: Discussionmentioning

confidence: 99%

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia

et al. 2020

View full text Add to dashboard Cite

Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has become an increasingly important parameter for treatment selection. Bosutinib is a TKI approved for CP CML in newly diagnosed adults and in those resistant or intolerant to prior therapy. In the Bosutinib Trial in First-Line Chronic Myelogenous Leukemia Treatment (BFORE), bosutinib demonstrated a significantly higher major molecular response rate compared with imatinib, with maintenance of HRQoL (measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire), after 12 months of first-line treatment. We examined relationships between molecular response (MR) and HRQoL. MR values were represented by a log-reduction scale (MRLR; a continuous variable). A repeated-measures longitudinal model was used to estimate the relationships between MRLR as a predictor and each FACT-Leu domain as an outcome. Effect sizes were calculated to determine strength of effects and allow comparisons across domains. The majority of FACT-Leu domains (with the exception of social well-being and physical well-being) demonstrated a significant relationship with MRLR (p < 0.05). Our results showed variable impact of clinical improvement on different dimensions of HRQoL. For patients who achieved MR5, emotional well-being and leukemia-specific domains showed the greatest improvement, with medium differences in effect sizes, whereas social well-being and physical well-being had the weakest relationship with MR.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition to their negative impact on non‐cancer mortality and overall survival, comorbidities negatively affect quality of life in cancer survivors (Arredondo et al, ; Efficace et al, ). Therefore, it is critical for nurses to attempt to prevent and sufficiently manage their patients' existing comorbidities in survivorship care.…”

Section: Discussionmentioning

confidence: 99%

Similarities and differences in the correlates of comorbidities in US male and female adult cancer survivors

Park

Strauß

2019

Public Health Nursing

View full text Add to dashboard Cite

Objectives To determine both the common and the sex‐specific correlates of comorbidities in adult male and female cancer survivors. Design Cross‐sectional study using the 2009–2014 National Health and Nutrition Examination Survey (NHANES). Sample Male (n = 667) and female (n = 772) cancer survivors 20 years of age and older. Measurements Questionnaire responses from NHANES provided data for this study. Comorbidities were assessed using a modified Charlson Comorbidity Index (CCI). Bivariate and multivariate linear regression analyses were conducted to identify correlates of comorbidities in male and female cancer survivors separately. Results The mean modified CCI score was 3.88 in males and 3.68 in females. Having a greater number of cancers diagnosed, being currently or formerly married, being physically inactive, having lower socioeconomic status, and being a former smoker were significant correlates of comorbidities in both males and females. Having a prostate cancer diagnosis was also a significant correlate of comorbidities in males. White race, more years since first cancer diagnosis, being overweight or obese, and having no more than a high school education were also significant correlates of comorbidities in females. Conclusions There are differences between correlates of comorbidities in male and female cancer survivors.

show abstract

“…Therefore, the question whether relatively early responses with TKI therapy could influence HRQoL outcomes in patients with CML-CP during long-term treatment remains unanswered. Most of the studies on HRQoL in patients with CML receiving TKI therapy are cross-sectional [ 14 , 21 ] and longitudinal studies with long-term follow-ups, with a limited number of such studies in Asian patients are rare.…”

Section: Introductionmentioning

confidence: 99%

Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study

et al. 2018

View full text Add to dashboard Cite

BackgroundTo assess the relationship between responses within 1 year and health-related quality of life (HRQoL) outcomes by exploring profiles of patients with CML-CP who were treated with front-line imatinib or nilotinib.MethodsA prospective, longitudinal, single-center study was conducted to assess the response to treatment with imatinib or nilotinib and the HRQoL profile of patients who were newly diagnosed with CML in chronic phase enrolled in the ENESTchina study.ResultsFifty-nine patients were randomized to receive imatinib (n = 31) or nilotinib (n = 28). With a median follow-up of 5 years, there was no difference in HRQoL profile observed between patients receiving imatinib and nilotinib. Achieving optimal response at 12 months was associated with better role limitations due to physical health problems (RP; P = 0.0019) and emotional problems (RE; P = 0.0110) and was the sole factor associated with significantly improving physical component summary over time (PCS; P = 0.0160). Achieving optimal response at 6 months had high probability of better physical functioning (PF; P = 0.0674), better social functioning (SF; P = 0.0571), and reduced role limitations due to emotional problems (RE; P = 0.0916). In addition, factors including age < 40 years, female gender, and higher level of education were also associated with better HRQoL subscale scores. However, optimal response at 3 months had no impact on HRQoL profile. The proportions of patients with failure-free survival and PFS at 5 years were significantly higher among patients who achieved optimal response at 3, 6, or 12 months than among those who did not achieve optimal response (warning or failure), and the OS rate at 5 years was significantly higher among those who achieved optimal response at 12 months. In a multivariate analysis, treatment received (nilotinib vs imatinib) was identified as an independent factor for the achievement of optimal response at both 6 months (OR, 3.9; 95% CI, 1.0–14.9) and 12 months (OR, 5.6; 95% CI, 1.7–17.9).ConclusionsAchieving optimal response at 12 months was not only associated with longer OS and reduced treatment failure rates and disease progression but also better HRQoL in newly diagnosed patients with CML-CP receiving front-line tyrosine kinase inhibitor treatment.Trial registrationChinese Clinical Trial Registry (http://www.chictr.org.cn): ChiCTR-OCH-11001699.

show abstract

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

Cited by 19 publications

References 28 publications

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia

Similarities and differences in the correlates of comorbidities in US male and female adult cancer survivors

Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study

Contact Info

Product

Resources

About